Main problems in pharmaceutical industry

The problems of large, small, scattered and chaotic pharmaceutical enterprises are prominent, and there is a lack of large leading enterprises. There are 36 pharmaceutical industrial enterprises in China, including 423 large enterprises, accounting for only 1 1.7% of the total. Most enterprises are not highly specialized and lack their own brands and characteristic varieties. Most enterprises are not only small in scale, poor in production conditions, backward in technology, outdated in equipment and low in management level, but also scattered in layout, and their production concentration is far below the level of advanced countries. In 2000, the production concentration of the top 60 pharmaceutical companies in China was 35.7%, while the sales of the top 20 pharmaceutical companies in the world accounted for about 60% of the world pharmaceutical market.

2. The enterprise-centered technological innovation system has not yet formed.

The foundation of new drug innovation is weak, the mechanism of medical technological innovation and rapid industrialization of scientific and technological achievements has not yet been fully formed, the investment in medical science and technology is insufficient, and there is a lack of new products with independent intellectual property rights in China, which leads to slow product renewal and serious duplication. 97% of the varieties of chemical raw materials are imitation products. There are many old products and few new products; There are many low-grade and low value-added products, but few high-tech and high value-added products; There are many varieties of repeated production and few exclusive brands. Some products such as gentamicin, paracetamol, vitamin B 1 and metronidazole are produced by dozens or even hundreds of enterprises. Even for new products, the phenomenon of repeated production is very serious. For example, there are 34 enterprises producing levofloxacin preparations and 35 enterprises producing clarithromycin preparations.

The pace of applying high technology to transform traditional industries is slow. Most old products have low technical and economic indicators, backward technology, high cost and lack of international competitiveness.

3. The pharmaceutical circulation system is not perfect.

After the three-level wholesale pattern formed under the planned economy system was basically broken, the new and effective drug circulation system has not yet been fully formed, and the illegal drug market has been repeatedly banned. Coupled with years of low-level repeated construction in the production field, the supply of most varieties exceeds demand seriously, the circulation order is chaotic, and the task of governance is arduous. But now leading pharmaceutical circulation enterprises such as Jiuzhoutong, Sinopharm Holdings and China Resources are merging commercial companies on a large scale to change the current pharmaceutical market.

4. The quality and performance of medical devices are very poor.

Most of the medical devices that can be produced in China are conventional middle and low-grade products with low added value, while most of the high-precision medical devices and new practical medical equipment needed for clinical use need to be imported. Conventional medical devices are slow to update, with low technology content, and the product quality can not meet the requirements of high-quality medical care. The repair rate and downtime rate of products are higher than those of similar foreign products, and the reliability of products is unstable.

5. The variety of preparation does not match the variety of raw materials.

China is a big producer of raw materials in the world, but the technical development and research of pharmaceutical preparations are not enough, the level of preparations is low, and the quality of most preparations is not high, so it is difficult to enter the international market. In China, an ordinary API can only be made into three preparations, while a foreign API can be made into dozens or even dozens of preparations; The preparation process is backward, and the quality stability of the preparation product is not high.

6. The import and export structure of pharmaceutical products is unreasonable.

China has not got rid of the traditional export mode of chemical raw materials, routine surgical instruments, sanitary materials and Chinese herbal medicines with low added value and heavy pollution, but imported expensive preparations and large-scale high-end medical equipment, and the export ratio of high-tech products is low.

The international market development is not strong enough, the information channels are not smooth, and the response to international market information is slow. In particular, there is a lack of awareness and mechanism to jointly explore the international market.